20231030-西南证券-新产业-300832.SZ-2023年三季报点评_业绩高速增长_海外市场拓展符合预期_5页_1mb

• Company Performance Overview: The report covers New Industry (300832)'s Q3 2023 earnings, highlighting strong growth in both revenue and profits. For the quarter, revenue reached 104 billion CNY, representing an 186% increase from the previous year, while net profit was 44 billion CNY, up 23%. Cumulative for the first nine months of 2023, revenue grew by 266% to 291 billion CNY, and net profit by 284% to 119 billion CNY.

• Growth Drivers: Key factors include increased sales of chemical luminometers, with X8 luminometer installations reaching 646 units in 2023. Overseas expansion is a major focus, with international revenue growing by an average of over 30%, driven by successful entry into new markets through 8 subsidiaries and local strategies. This has led to improved gross margins (744% in Q3) and efficient cost management, despite higher sales expenses due to post-pandemic activities.

• Financial and Operational Highlights: The company demonstrates strong margins and expense control, with Q3 gross margin at 744% (up 39 points from prior periods), indicating potential for further margin expansion. Domestic revenue grew 242%, while overseas performance was stronger at around 30% year-over-year, showcasing effective internationalization.

• Investment Recommendation and Valuation: The analyst maintains a "Buy" rating, with expected revenue and profit projections for 2023-2025 showing substantial growth, including a PE ratio of 17 times by 2025. The report projects steady rise in earnings, supported by export-driven strategies.

• Risks and Challenges: Potential risks include regulatory changes (e.g., medical device procurement), slower-than-expected overseas sales, increased competition, and macroeconomic factors like currency fluctuations. These could impact future growth and profitability.

The analysis concludes that New Industry is well-positioned for continued growth, bolstered by its domestic roots and international reach, making it a compelling investment opportunity despite existing risks.